- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in BioNTech
Pfizer Vaccine Trial Success Signals Breakthrough In Pandemic Battle
Shares of other vaccine developers in the final stage of testing also rose with Johnson & Johnson up nearly 4% and Moderna Inc, whose vaccine uses a similar technology as the Pfizer shot, up more than 8%.
Read MoreAustralia signs COVID-19 vaccine deals with Novavax, Pfizer
Australia signs COVID-19 vaccine deals with Novavax, Pfizer
Read More
Australia Signs Two More COVID-19 Vaccine Deals
The Pfizer-BioNTech vaccine along with AstraZeneca's and Novavax's are among the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.
Read More
China's Fosun To Seek Approval For Biontech's COVID-19 Second Vaccine, Ends Trials On First
Fosun is licensed to exclusively develop and commercialize COVID-19 vaccine products developed by using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan.
Read More
Dow Advances, S&P Ekes Out Gain As Vaccine Timeline Comes Into Focus
The Dow Jones Industrial Average rose 112.11 points, or 0.39%, to 28,606.31, the S&P 500 gained 0.47 points, or 0.01%, to 3,483.81 and the Nasdaq Composite dropped 42.32 points, or 0.36%, to 11,671.56.
Read More
Pfizer Says Earliest US Filing For COVID-19 Vaccine Would Be Late November
Pfizer's shares were up 3.5% in afternoon trading, while BioNTech's U.S.-listed shares were up 3.9%. Moderna shares fell 1.5%.
Read More
New Zealand Signs Deal With Pfizer, Biontech For COVID-19 Vaccine
The Pfizer-BioNTech vaccine is one of the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.
Read More
EU Reviewing Pfizer-Biontech COVID-19 Vaccine In Real Time
Pfizer and BioNTech said in a joint statement the start of the review is based on data from laboratory and animal testing, as well as early testing on humans
Read More
Pfizer Says Late-Stage Coronavirus Vaccine Study Shows Moderate Side Effects
The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.
Read More
BioNTech Wins $445 Million German Grant For COVID-19 Vaccine
BioNTech and Pfizer are already testing their most promising vaccine candidate in late-stage trials and have started recruiting patients in the United States, Brazil, Argentina and Europe.
Read More
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold Over Safety Concern
Shares of AstraZeneca fell more than 8% in after-hours U.S. trading, while shares of rival vaccine developers rose. Moderna Inc was up more than 4% and Pfizer Inc rose less than 1%.
Read More
Japan Says In Deal To Purchase Astrazeneca's COVID-10 Vaccine
The agreement comes after Japan announced a deal last week to buy 120 million doses of a COVID-19 vaccine candidate developed by Pfizer Inc and BioNTech SE.
Read More
Pfizer-BioNTech Begin Late-Stage Study Of Lead COVID-19 Vaccine Candidate
Patients are each given two doses of the drugmakers’ vaccine to help boost immunity, so the first 100 million doses would vaccinate around 50 million people.
Read MoreUS To Pay Pfizer, Biontech $1.95 Billion For 100 Million Doses Of Covid-19 Vaccine
According to the latest data from Johns Hopkins University, worldwide, the number of coronavirus cases has surged to 15,177,477 while the death toll has risen to 621,890.
Read More
US To Pay Pfizer, Biontech $1.95 Billion For COVID-19 Vaccine
Pfizer hopes to start its pivotal late-stage trial of the vaccine as early as next week, pending regulatory approvals, Chief Scientific Officer Mikael Dolsten said in an interview.
Read More